Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.76 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation 3D Report Full Report

Validation slider image for 9DH3

This is version 1.1 of the entry. See complete history

Literature

Navigating from cellular phenotypic screen to clinical candidate: selective targeting of the NLRP3 inflammasome.

Matico, R.Grauwen, K.Chauhan, D.Yu, X.Abdiaj, I.Adhikary, S.Adriaensen, I.Aranzazu, G.M.Alcazar, J.Bassi, M.Brisse, E.Canellas, S.Chaudhuri, S.Delgado, F.Dieguez-Vazquez, A.Du Jardin, M.Eastham, V.Finley, M.Jacobs, T.Keustermans, K.Kuhn, R.Llaveria, J.Leenaerts, J.Linares, M.L.Martin, M.L.Martin-Perez, R.Martinez, C.Miller, R.Munoz, F.M.Muratore, M.E.Nooyens, A.Perez-Benito, L.Perrier, M.Pietrak, B.Serre, J.Sharma, S.Somers, M.Suarez, J.Tresadern, G.Trabanco, A.A.Van den Bulck, D.Van Gool, M.Van Hauwermeiren, F.Varghese, T.Vega, J.A.Youssef, S.A.Edwards, M.J.Oehlrich, D.Van Opdenbosch, N.

(2025) EMBO Mol Med 17: 54-84

  • DOI: https://doi.org/10.1038/s44321-024-00181-4
  • Primary Citation Related Structures: 
    9DH3

  • PubMed Abstract: 

    The NLRP3 inflammasome plays a pivotal role in host defense and drives inflammation against microbial threats, crystals, and danger-associated molecular patterns (DAMPs). Dysregulation of NLRP3 activity is associated with various human diseases, making it an attractive therapeutic target. Patients with NLRP3 mutations suffer from Cryopyrin-Associated Periodic Syndrome (CAPS) emphasizing the clinical significance of modulating NLRP3. In this study, we present the identification of a novel chemical class exhibiting selective and potent inhibition of the NLRP3 inflammasome. Through a comprehensive structure-activity relationship (SAR) campaign, we optimized the lead molecule, compound A, for in vivo applications. Extensive in vitro and in vivo characterization of compound A confirmed the high selectivity and potency positioning compound A as a promising clinical candidate for diseases associated with aberrant NLRP3 activity. This research contributes to the ongoing efforts in developing targeted therapies for conditions involving NLRP3-mediated inflammation, opening avenues for further preclinical and clinical investigations.


  • Organizational Affiliation
    • Janssen Research & Development, LLC, Discovery Technologies and Molecular Pharmacology (DTMP), Spring House, PA, 19044, USA.

Macromolecule Content 

  • Total Structure Weight: 576.94 kDa 
  • Atom Count: 37,752 
  • Modeled Residue Count: 4,724 
  • Deposited Residue Count: 5,068 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Maltose/maltodextrin-binding periplasmic protein,NACHT, LRR and PYD domains-containing protein 3 chimera
A, B, C, D
1,267Homo sapiensMutation(s): 0 
Gene Names: malEb4034JW3994NLRP3C1orf7CIAS1NALP3PYPAF1
EC: 3.6.4
UniProt & NIH Common Fund Data Resources
Find proteins for P0AEX9 (Escherichia coli (strain K12))
Explore P0AEX9 
Go to UniProtKB:  P0AEX9
Find proteins for Q96P20 (Homo sapiens)
Explore Q96P20 
Go to UniProtKB:  Q96P20
PHAROS:  Q96P20
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupsQ96P20P0AEX9
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 3 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
CPS

Query on CPS



Download:Ideal Coordinates CCD File
G [auth A],
J [auth B],
M [auth C],
P [auth D]
3-[(3-CHOLAMIDOPROPYL)DIMETHYLAMMONIO]-1-PROPANESULFONATE
C32 H58 N2 O7 S
UMCMPZBLKLEWAF-BCTGSCMUSA-N
ADP

Query on ADP



Download:Ideal Coordinates CCD File
E [auth A],
H [auth B],
K [auth C],
N [auth D]
ADENOSINE-5'-DIPHOSPHATE
C10 H15 N5 O10 P2
XTWYTFMLZFPYCI-KQYNXXCUSA-N
A1A4L
(Subject of Investigation/LOI)

Query on A1A4L



Download:Ideal Coordinates CCD File
F [auth A],
I [auth B],
L [auth C],
O [auth D]
2-[(4S)-5-ethyl-8-oxothieno[2',3':4,5]pyrrolo[1,2-d][1,2,4]triazin-7(8H)-yl]-N-(pyrimidin-4-yl)acetamide
C16 H14 N6 O2 S
CWNJFZLUBUHIRK-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.76 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Structure Validation

View Full Validation Report



Entry History 

& Funding Information